This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no disease modifying…
- Investigator
- Torge Rempe
- Ages
- 18 Years - 65 Years
- Sexes
- All